Abstract
Background Shingles vaccination protects against Alzheimer’s disease (AD), which is related to herpes virus infection. In the current analysis we attempted to determine if herpes zoster vaccination might reduce the risk of PD.
Methods Data on PD prevalence by US state is from Mantri et al, Table 1. They identified 27,538,023 Medicare beneficiaries that met inclusion criteria, of whom 392,214 had a PD diagnosis in 2014. Data on Shingles vaccination among adults aged 60 and over, United States, 2018 is from Terlizzi and Black, Figure 4. The NHIS data from 2008 to 2018 were used for this investigation. The NHIS is a household survey of the civilian, non-institutionalized U.S. population that is conducted nationally. It is continually carried out by the National Center for Health Statistics during the entire year (NCHS). Although follow-ups to completed interviews may be made over the phone, interviews are conducted in respondents’ homes.
Results States with the most PD (lowest age adjusted prevalence ranks) had the lowest proportion of adults aged 60 and over who had ever received a shingles vaccine. Increased vaccination proportion led to significantly reduced female PD prevalence. Increased proportion of Medicare-Medicaid dual eligibility and increased health care spending were associated with diminished proportion of adults who had ever received a shingles vaccine.
Conclusion Shingles vaccination is a wise, cost-effective public health measure that may reduce PD and AD prevalence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health under award numbers S10OD018522 and S10OD026880. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was also supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding sources: Research reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health under award numbers S10OD018522 and S10OD026880. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was also supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai.
Data sources described in article all publicly available.
Conflicts of interest: none